Orris

https://orris.care/shared/chat/6e7a231c-3e44-4f33-8ad1-97093810a5cd

Reading Web Page
That shared chat is titled "Recent Updates in Chronic Liver Disease" - a previous Orris session that researched the latest developments (2024-2026) in chronic liver disease management. Here's a summary of what was covered:

Recent Updates in Chronic Liver Disease (2024-2026)

1. Nomenclature Shift

The field has moved to the SLD (Steatotic Liver Disease) framework, replacing older terms like NAFLD/NASH with MASLD/MASH.

2. MASLD/MASH - Two FDA-Approved Treatments

  • Resmetirom (Rezdiffra) - FDA approved March 2024; a thyroid hormone receptor-beta (THR-β) agonist for MASH with fibrosis
  • Semaglutide (Wegovy 2.4 mg/week SC) - FDA approved August 2025 for MASH with stage F2-F3 fibrosis
  • Pipeline agents: Efruxifermin and Pemvidutide in trials
  • Meta-analytic evidence supporting GLP-1 receptor agonist therapy

3. Major Guideline Updates

GuidelineYear
EASL-EASD-EASO MASLD joint guidelines2024
APASL MAFLD guidelines2025
EASL Autoimmune Hepatitis guidelines2025
AASLD/IDSA Chronic Hepatitis B guidelinesNovember 2025
Chinese Cirrhosis guidelines2025

4. Cirrhosis Complications

  • Portal Vein Thrombosis (PVT): AGA 2025 best practice advice - DOACs now acceptable in cirrhosis
  • Non-invasive diagnostics: FibroScan (liver stiffness measurement) accepted as an FDA surrogate endpoint (2025)
  • Updated HRS (Hepatorenal Syndrome) management

5. Hepatitis B - Moving Toward Functional Cure

  • AASLD/IDSA updated guidelines (November 2025)
  • New agents in the functional cure pipeline

6. Liver Transplantation

  • New AASLD/AST transplant guidelines (2025-2026)
Would you like me to expand on any of these topics - such as the details of resmetirom's mechanism, the new CHB functional cure strategies, or the updated portal hypertension management?

https://orris.care/shared/chat/6e7a231c-3e44-4f33-8ad1-97093810a5cd

That's the same shared chat link from your previous message - the "Recent Updates in Chronic Liver Disease (2024-2026)" session we just reviewed together.
Here's a quick recap of what it contained:
  • MASLD/MASH: Two FDA-approved drugs - Resmetirom (2024) and Semaglutide (2025)
  • Guidelines: EASL-EASD-EASO, APASL, EASL AIH, AASLD/IDSA CHB, and Chinese Cirrhosis guidelines (2024-2025)
  • Cirrhosis: DOACs now acceptable for PVT; FibroScan as FDA surrogate endpoint
  • Hepatitis B: Functional cure pipeline updates
  • Liver Transplant: New AASLD/AST guidelines (2025-2026)
Is there a specific topic from that session you'd like me to go deeper on?

elaborate all guideline in detail

Searching PubMed

EASL EASD EASO MASLD clinical practice guidelines 2024

Searching PubMed

AASLD IDSA chronic hepatitis B treatment guidelines 2025

Searching PubMed

EASL autoimmune hepatitis clinical practice guidelines 2025

Reading Article
Reading Article
Searching PubMed

chronic hepatitis B treatment guidelines antiviral 2025

Searching PubMed

portal vein thrombosis cirrhosis AGA management 2025

Reading Article
Reading Article
Searching the Web

APASL MAFLD guidelines 2025 key recommendations metabolic associated fatty liver

Searching PubMed

cirrhosis management guidelines complications China 2025

Reading Article
Reading Web Page

APASL MAFLD 2025 guidelines key recommendations diagnosis treatment fibrosis

Searching PubMed

liver transplantation guidelines AASLD 2025 selection criteria outcomes

Reading Article
Reading Article
Searching the Web

AASLD IDSA hepatitis B guidelines 2025 treatment indications functional cure recommendations

Reading Article
Reading Web Page

AASLD IDSA 2025 hepatitis B treatment indications immune tolerant phase grey zone antiviral discontinuation

All 8 guidelines have been fully elaborated above. Here's a quick navigation guide:
  1. EASL-EASD-EASO MASLD 2024 - Resmetirom indications, stepwise FIB-4 → FibroScan algorithm, nomenclature shift
  2. APASL MAFLD 2025 - Asian-specific thresholds, age-adjusted FIB-4, resmetirom patient selection
  3. EASL AIH 2025 - Pediatric guidance, variant syndromes, acute severe AIH → early LT listing
  4. AASLD/IDSA CHB Nov 2025 - "Grey zone" management, immune-tolerant treatment >40 yrs, conservative NUC discontinuation, HCC surveillance expansion
  5. EASL HBV 2025 - Functional cure biomarkers (HBcrAg, HBV RNA), 10-section global framework
  6. Chinese Cirrhosis 2025 - Re-compensation stage, cirrhosis reversal, HRS terlipressin protocols
  7. AGA PVT 2025 - 10 Best Practice Advice statements, DOACs now acceptable in Child-Pugh A/B
  8. AASLD/AST Liver Transplant 2025-26 - Machine perfusion, recurrent MASLD post-transplant, expanded donor criteria
Let me know if you want deeper detail on any of these!
This is a shared conversation. Sign in to Orris to start your own chat.